Press Release

25th August, 2026 Corporate Relationship Department The Manager - Listing M/s. BSE Limited M/s. National Stock Exchange of India Ltd Mumbai 400001 Bandra (E), Mumbai 400051 Scrip Code: 524816 Scrip Code: NATCOPHARM Dear Sir/Madam, Sub:- Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 With reference to the above cited subject, please find enclosed herewith the Disclosure and Press Release under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 regarding the investment in eGenesis, Inc. This is for your information and records. Thanking you, Yours faithfully, For NATCO Pharma Limited Ch. Venkat Ramesh Company Secretary & Compliance Officer Encl: As above Natco Pharma Limited Regd. Off. Press Release NATCO Pharma Ltd NATCO House Road No.2, Banjara Hills Hyderabad-500 034, India Hyderabad, India, August 25th, 2026: NATCO Pharma Limited (BSE: 524816 and NSE: NATCOPHARM) ("NATCO") Natco Pharma Limited is investing US$ 14 million in eGenesis, Inc. through its wholly owned subsidiaries, NATCO Pharma (Canada) Inc. for an amount of US$ 9.5 million and NATCO Pharma South Africa Proprietary Limited for an amount of US$ 4.5 million, though convertible promissory notes. Previously in 2024, NATCO Pharma Limited had invested US$ 8 million in eGenesis, Inc. through preferred stock. The total investment made by NATCO Pharma Limited in eGenesis, Inc. now stands at US$ 22 million. eGenesis is pioneering a genome engineering-based approach in the development of safe and effective transplantable organs to end the global organ shortage and transform the treatment of organ failure. The eGenesis Genome Engineering and Production (EGEN™) Platform is the only technology of its kind to comprehensively address cross-species molecular incompatibilities and viral risk via genetic engineering to improve the lives of patients in need of a transplant. eGenesis is advancing development programs for kidney transplant, acute liver failure, and heart transplant. In March 2024, eGenesis announced the world’s first porcine kidney transplant in a living patient. The transplant was authorized by the U.S. Food & Drug Administration (FDA) under the Expanded Access pathway. It was followed by porcine kidney transplants in additional two patients. The outcomes have been exceptionally positive. About NATCO Pharma Limited NATCO Pharma Limited (www.natcopharma.com), (NSE:NATCOPHARM, BSE: 524816, Reuters: NATP.NS, Bloomberg: NTCPH,) headquartered at Hyderabad, India, develops, manufactures and distributes generic and branded pharmaceuticals, specialty pharmaceuticals, active pharma ingredients and crop protection products. The Company is a R&D oriented, and a science driven, leading Oncology player in the targeted therapies of domestic market and focuses on limited competition molecule in the US. The Company’s different manufacturing facilities are approved by several leading regulatory authorities like US FDA, Brazil ANVISA, Health Canada, WHO and others catering to 50+ global markets. For more information, please visit us at www.natcopharma.com or click on LinkedIn or X (formerly Twitter). About eGenesis, Inc. eGenesis, Inc. is a biotechnology company based in Cambridge, Massachusetts, USA, focused on using its multiplex gene editing and genome engineering platform to transform solid organ and therapeutic cell transplantation for the treatment of serious diseases. For further information please contact: Rajeev Menon - Investor Relations ir@natcopharma.co.in/r.menon@natcopharma.co.in Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 Investment of US$ 14 million in eGenesis, Inc. by NATCO Pharma (Canada) Inc. for an amount of US$ 9.5 million and NATCO Pharma South Africa Proprietary Limited for an amount of US$ 4.5 million through convertible promissory notes Sl. Particulars Details of Investment A Name of the target entity, details in brief 1) Name of the target entity such as size, turnover etc. eGenesis, Inc. 2) Details in brief such as size, turnover etc. It is an R&D company engaged in using its multiplex gene editing and genome engineering platform to research and develop porcine solid organ donors for use in human transplantation for patients with serious diseases causing organ failure. B Whether the acquisition would fall No within related party transaction(s) and whether the promoter/ promoter group/ group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at “arm’s length” C Industry to which the entity being Biotechnology acquired belongs D Objects and effects of acquisition Investing in new-age therapeutic programmes (including but not limited to, disclosure addressing critical unmet medical needs of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity) E Brief details of any governmental or - regulatory approvals required for the acquisition F Indicative time period for completion of September 30, 2026 the acquisition; G Nature of consideration - whether cash Cash consideration for subscribing to convertible consideration or share swap and details notes of the same H Cost of acquisition or the price at which US$ 9.50 million by NATCO Pharma (Canada) the shares are acquired Inc. and US$ 4.50 million by NATCO Pharma South Africa Proprietary Limited Sl. Particulars Details of Investment I Percentage of shareholding / control NATCO Pharma (Canada) Inc. is purchasing a acquired and / or number of shares Convertible Promissory Note with a principal acquired amount of US$ 9.50 million with an interest rate of 8% compounded annually and NATCO Pharma South Africa Proprietary Limited is purchasing a Convertible Promissory Note with a principal amount of US$ 4.50 million with an interest rate of 8% compounded annually. At the time of completion of this acquisition, no additional shares are being acquired. J brief background about the entity 1. Brief background: acquired in terms of products/line of business acquired, date of eGenesis, Inc. is a clinical stage company incorporation, history of last 3 years engaged in using its multiplex gene editing and turnover, country in which the acquired genome engineering platform to address entity has presence and any other numerous mechanisms of human rejection of significant information (in brief) non-human organs. The company is currently in clinical trials for porcine kidney transplantation in humans and porcine liver perfusion with a goal of addressing the fundamental limitation of human donor availability for patients with serious diseases resulting in acute and chronic organ failure. 2. Line of business: Biotechnology 3. Date of incorporation: October 1, 2015 4. Turnover of last 3 years ending December 31 (in US$ million): The company is a clinical stage company and pre-revenue 5. Country in which the acquired entity will have presence: United States of America